1. Volume 151, Issue 2, Pages 340-357 (February 2017)
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD 
Fernando J. Martinez, MD, FCCP, Klaus F. Rabe, MD, PhD, Gary T. Ferguson, MD, FCCP, Leonardo M. Fabbri, MD, FCCP, Stephen Rennard, MD, FCCP, Gregory J. Feldman, MD, Sanjay Sethi, MD, Selwyn Spangenthal, MD, Gregory M. Gottschlich, MD, Roberto Rodriguez-Roisin, MD, PhD, FCCP, Samir Arora, MD, Thomas M. Siler, MD, FCCP, Shahid Siddiqui, MD, MHSA, Patrick Darken, PhD, Tracy Fischer, PharmD, Andrea Maes, PhD, Michael Golden, MS, Chad Orevillo, MPH, Colin Reisner, MD, FCCP 
CHEST 
Volume 151, Issue 2, Pages (February 2017)
DOI: /j.chest
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Patient disposition diagrams. FF = formoterol fumarate 9.6 μg; GFF = glycopyrrolate/formoterol fumarate 18/9.6 μg; GP = glycopyrrolate 18 μg; ITT = intent to treat; MDI = metered dose inhaler.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2
Study design. HFA = hydrofluoroalkane. See Figure 1 legend for expansion of other abbreviations.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 The Authors Terms and Conditions

4. Figure 3
Mean change (± SE) from baseline in trough morning predose FEV1 over 24 weeks by treatment arm for each study (ITT population). See Figure 1 legend for expansion of abbreviations.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 The Authors Terms and Conditions

5. Figure 4
Mean change (± SE) from baseline in peak FEV1 within 2 hours postdose over 24 weeks by treatment arm for each study (ITT population). See Figure 1 legend for expansion of abbreviations.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 The Authors Terms and Conditions